PLYMOUTH MEETING, PA — Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) will report second-quarter 2026 financial results on Aug. 4 before U.S. markets open, giving investors an updated view of the rare disease drugmaker’s financial performance and commercial operations.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time the same day to discuss the quarterly results, Harmony said.
Investors participating by phone can dial 800-347-6865 within the United States or 203-518-9757 internationally and use passcode HRMYQ226. The company recommends joining the call at least 10 minutes before it begins.
A live webcast and replay will be available through Harmony’s investor relations website at https://ir.harmonybiosciences.com/.
Harmony Biosciences, headquartered in Plymouth Meeting, Pennsylvania, develops and commercializes therapies for rare neurological diseases. The company was established in 2017 by Paragon Biosciences LLC.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.